SMARCA1 and lung cancer: We performed a meta-analysis (Fig 7) to validate the correlation observed in breast cancer (P = 0.001), lung cancer, ovarian cancer and gastric cancer (all P < 0.001) again and to identify any potential SMARCA1-prognosis correlation in liver cancer (P = 0.021).